DOMINIQUE LEVEQUE: Open Payments
NPI 1285785584 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,293 in 237 payments from 20 companies in 2025. Trend: 2023 $3,640 · 2024 $4,139 · 2025 $5,293
Food & beverage: $5,081Education: $211
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 36 | $872 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $610 |
| E.R. Squibb & Sons, L.L.C. | 18 | $491 |
| Alkermes, Inc. | 25 | $405 |
| Otsuka America Pharmaceutical, Inc. | 25 | $399 |
| Vanda Pharmaceuticals Inc. | 15 | $361 |
| Axsome Therapeutics, Inc. | 10 | $349 |
| JAZZ PHARMACEUTICALS INC. | 13 | $332 |
| Neurocrine BioSciences, Inc. | 11 | $303 |
| ABBVIE INC. | 16 | $259 |
Products named: CAPLYTA, COBENFY, REXULTI, AUSTEDO XR, ARISTADA, HETLIOZ, Auvelity, EPIDIOLEX.
Industry payments across IN — which companies pay providers there.
